Synergistic Reduction of TNF-α by Combined Ursodeoxycholic Acid and Multi-Strain Probiotics in a Rat Model of Cholestasis
DOI:
https://doi.org/10.37275/bsm.v10i9.1651Keywords:
Cholestasis, Gut–liver axis, Probiotics, TNF-α, Ursodeoxycholic acidAbstract
Background: Cholestasis is a complex hepatobiliary disorder in which impaired bile flow provokes a sustained inflammatory response, with tumor necrosis factor-alpha (TNF-α) acting as a central pro-inflammatory mediator. Ursodeoxycholic acid (UDCA) is the first-line therapy, but a substantial subset of patients responds incompletely, motivating adjunctive strategies that target extrahepatic, gut-derived drivers of inflammation through the gut–liver axis.
Objective: To evaluate whether multi-strain probiotics potentiate the anti-inflammatory (TNF-α–lowering) effect of ursodeoxycholic acid (UDCA) in experimental cholestasis.
Methods: This randomised, post-test-only controlled experimental study was reported in accordance with ARRIVE 2.0 guidelines. Thirty-five male Sprague-Dawley rats were randomised into seven groups (n=5): healthy control (K1), disease control (K2), UDCA monotherapy (K3), probiotic monotherapy (K4), and three UDCA plus dose-escalating probiotic combinations (K5–K7). Cholestasis was induced by common bile duct ligation; interventions ran for 21 days. Serum TNF-α was quantified by ELISA and analysed with one-way ANOVA, Tukey HSD and Games-Howell post hoc tests, effect sizes, and dose-response regression.
Results: TNF-α differed markedly across groups (F(6,28)=783.5, p<0.001, η²=0.994). Ligation raised TNF-α from 5.69±0.25 pg/mL (K1) to 17.88±0.43 pg/mL (K2; p<0.001, Cohen's d=34.7). Both monotherapies reduced TNF-α (K3 14.91±0.49; K4 12.50±0.32; both p<0.001), but combination therapy achieved significantly greater suppression, lowest in K7 (7.91±0.18 pg/mL; 55.8% reduction; 81.8% normalisation toward healthy). A significant dose-dependent decline occurred across combination groups (slope=−0.113 pg/mL per mg, r=−0.94, R²=0.89, p<0.001).
Conclusion: Combined UDCA and probiotics produce a synergistic, dose-dependent reduction of TNF-α in experimental cholestasis, supporting probiotics as a rational adjunct targeting the gut–liver axis and warranting translational evaluation in cholestatic patients.
Authors
- Muhammad Hasbi Nur1*
- Erik Prabowo1
- Sigit Adi Prasetyo1
- 1Department of Surgery, Faculty of Medicine, Universitas Diponegoro/Dr. Kariadi General Hospital, Semarang, Indonesia
Corresponding author Muhammad Hasbi Nur — muhammadhasbinur99@gmail.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
Copyright and licensing
Copyright in each article remains with the author(s). Authors grant Bioscientia Medicina: Journal of Biomedicine and Translational Research a non-exclusive right of first publication and the right to identify itself as the original publisher. No exclusive transfer of copyright is required.
All articles are published under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0): https://creativecommons.org/licenses/by-nc-sa/4.0/. Users may copy, redistribute, remix, transform, and build upon the material for non-commercial purposes, provided appropriate attribution is given, a link to the license is supplied, changes are indicated, and adaptations are distributed under the same license.
The license applies to the article's scholarly content unless a credit line states otherwise. Third-party material may be subject to separate rights. Authors retain patent, trademark, moral, and research-data rights. The copyright year follows the article's publication date.
